Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

Conditions

• Gastroesophageal Peritoneal Carcinomatosis
• Synchronous Gastric Peritoneal Carcinomatosis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Cisplatin — DRUG
  Cisplatin interferes with DNA replication, which kills the fastest proliferating cells.
• Mitomycin C — DRUG
  A drug that slows down the growth of cancer cells by making them less able to create the DNA, RNA, and proteins they need to multiply.

Study Details

This trial will administer laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis from gastric cancer (GPC) who are receiving standard of care systemic chemotherapy.

Key Dates

Start date

Apr 30, 2026

Status verified

Mar 2026

Primary completion

Apr 30, 2030

Completion

Apr 30, 2034

Study Design

Enrollment

22 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Hyperthermic intraperitoneal chemotherapy (HIPEC)
  Combination of cisplatin (100 mg/m\^2) and mitomycin C (30 mg total, administered in 2 divided doses of 15 mg each, 45 minutes apart) in 3-liters of normal saline perfusate at 42°C for 90 minutes, with continuous manipulation of the abdomen to ensure even distribution.

Primary Outcome Measure

1-year Progression-free Survival (PFS) [ Time Frame: At 1 year ]

Central Contacts

• Debra Diecks, RN, BSN
  412-623-8364
  [email protected]
• Cole Stacy, RN, BSN
  878-261-6872
  [email protected]

Locations (1)

Find similar trials in Pittsburgh, PA